Espinoza Octavio, Chief Financial Officer of Ligand Pharmaceuticals (LGND), has demonstrated a consistent pattern of share disposals in recent months, with no offsetting purchases reported since at least late 2025. SEC filings reveal 58 total transactions exclusively in LGND stock, with a pronounced selling bias—$9.3 million in aggregate sales compared to just under $1 million in buys. The most recent activity shows a concentrated wave of sales in early March 2026, including a $687,825 disposition on March 11 and a series of eight transactions on March 4 totaling approximately $2.6 million. These disposals followed earlier sales in February 2026, including a $824,110 transaction on February 14 and multiple smaller sales that month.
The transactions include a mix of open-market sales (code S) and sales to cover tax obligations (code M), with no recent acquisitions beyond minor awards (code A) with zero reported value. The absence of any purchases since at least December 2025, when a small $765 award was recorded, suggests a sustained reduction in Espinoza’s LGND holdings. The sales, particularly the March transactions, represent significant liquidity events, with individual dispositions ranging from $10,604 to over $700,000. While the filings do not indicate the reasons for these transactions, the volume and timing—clustered in early March—point to a deliberate divestment strategy rather than routine diversification.
AI-assisted summary